•
Sep 30, 2021
Immunovant Q2 2022 Earnings Report
Reported financial results for the quarter ended September 30, 2021.
Key Takeaways
Immunovant reported a net loss of $37.7 million, or $0.35 per common share, for the quarter ended September 30, 2021. The company's research and development expenses were $21.4 million, and general and administrative expenses were $16.3 million. Immunovant ended the quarter with approximately $559 million in cash.
Ended the quarter with approximately $559 million in cash.
Research and development expenses were $21.4 million.
General and administrative expenses were $16.3 million.
Net loss was $37.7 million, or $0.35 per common share.